STK11 and neoplasm: Co‐occurring alterations with KRAS included FLT1 (28%, 9/32, p = 0.033), APC (16%, 5/32, p = 0.015), and KEAP1 (16%, 5/32), with four of these tumours also harbouring STK11 alterations, forming a KRAS‐KEAP1‐STK11 mutational profile (13%, 4/32).